Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00STL
|
||||
| Former ID |
DCL000360
|
||||
| Drug Name |
Nilotinib
|
||||
| Synonyms |
NIL; Nilotinibum; Tasigna; AMN 107; AMN107; AMN-107; Tasigna (Novartis); Nilotinib (INN/USAN); Nilotinib, AMN107, Tasigna; Tasigna, AMN-107, Nilotinib; L-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-(9CI); 4-Methyl-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo; 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; Nilotinib (BCR-ABL inhibitor 2nd gen)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Novartis AG
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C8H17N3O2
|
||||
| InChI |
InChI=1S/C8H17N3O2/c1-6(9)11-5-3-2-4-7(10)8(12)13/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13)/t7-/m1/s1
|
||||
| InChIKey |
ONYFNWIHJBLQKE-SSDOTTSWSA-N
|
||||
| CAS Number |
CAS 641571-10-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
L01XE08
|
||||
| Drug Resistance Mutation (DRM) | |||||
| DRM | DRM Info | ||||
| Target and Pathway | |||||
| Target(s) | Proto-oncogene c-Abl | Target Info | Modulator | [529282] | |
| PANTHER Pathway | Axon guidance mediated by Slit/Robo | ||||
| Pathway Interaction Database | p73 transcription factor network | ||||
| ATM pathway | |||||
| Regulation of Telomerase | |||||
| Posttranslational regulation of adherens junction stability and dissassembly | |||||
| Lissencephaly gene (LIS1) in neuronal migration and development | |||||
| PDGFR-beta signaling pathway | |||||
| Neurotrophic factor-mediated Trk receptor signaling | |||||
| Validated transcriptional targets of TAp63 isoforms | |||||
| p53 pathway | |||||
| Regulation of retinoblastoma protein | |||||
| Reactome | Regulation of actin dynamics for phagocytic cup formation | ||||
| CDO in myogenesis | |||||
| RHO GTPases Activate WASPs and WAVEs | |||||
| HDR through Single Strand Annealing (SSA) | |||||
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | |||||
| Factors involved in megakaryocyte development and platelet production | |||||
| WikiPathways | Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
| Fcgamma receptor (FCGR) dependent phagocytosis | |||||
| ATM Signaling Pathway | |||||
| Retinoblastoma (RB) in Cancer | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Pathogenic Escherichia coli infection | |||||
| Regulation of Microtubule Cytoskeleton | |||||
| Integrated Breast Cancer Pathway | |||||
| Signaling by Robo receptor | |||||
| Myogenesis | |||||
| Factors involved in megakaryocyte development and platelet production | |||||
| References | |||||
| Ref 529282 | 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. | ||||
| Ref 541038 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5697). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.